PDS Biotechnology Corporation
PDSB
|
$2.64
-8.97%
-9.85%
880K
|
Health Technology
(0.0% 1d) (-45.7% 1m) (-59.8% 1y) (-8.6% 2d) (-2.6% 3d) (-6.0% 7d) (-21.86% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 96,833,286
http://www.pdsbiotech.com
Sec Filling | Patents | 20 employees
(United States) PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.
covid breast cancer cancer prostate cancer immunotherapy injection
add to watch list Paper trade email alert is off
Press-releases
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
Published: 2024-03-27 (Crawled : 00:00) - biospace.com/
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: -10.71%
H: 8.5%
C: -3.75%
biotech year update financial results
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
Published: 2024-03-20 (Crawled : 12:00) - globenewswire.com
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: 0.21%
H: 6.38%
C: 2.34%
conference business year update financial results
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
Published: 2024-03-13 (Crawled : 12:00) - globenewswire.com
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: 3.78%
H: 5.27%
C: -1.04%
infectimune patent biotech publication research preclinical grant
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer
Published: 2024-01-22 (Crawled : 22:00) - globenewswire.com
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: 0.59%
H: 0.18%
C: -1.36%
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: 1.11%
H: 10.79%
C: 10.79%
biotech medical
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
Published: 2024-01-16 (Crawled : 13:00) - globenewswire.com
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: -5.0%
conference biotech
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-12-04 (Crawled : 22:00) - globenewswire.com
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: -0.38%
H: 1.9%
C: -0.38%
nasdaq grant
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
Published: 2023-11-28 (Crawled : 12:30) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.93%
H: 0.37%
C: -0.43%
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: -3.39%
H: 0.7%
C: -6.49%
PODD | $166.255 0.93% 0.92% 840K
|
Health Technology
|
| O: -0.87%
H: 1.19%
C: -0.21%
biotech financial
APYX MEDICAL CORPORATION APPOINTS MATTHEW HILL AS CHIEF FINANCIAL OFFICER
Published: 2023-11-28 (Crawled : 14:00) - apyxmedical.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -2.99%
H: 0.0%
C: 0.0%
SSKN | $0.56 5.15% 4.89% 75K
|
Health Technology
|
| O: -4.51%
H: 19.77%
C: 0.23%
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: -3.39%
H: 0.7%
C: -6.49%
APYX | $1.325 -3.99% -4.15% 57K
|
Health Technology
|
| O: 0.0%
H: 10.88%
C: 1.02%
corporation medical apyx financial
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-14 (Crawled : 12:30) - globenewswire.com
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: 6.57%
H: 15.36%
C: 11.25%
biotech business update financial results
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months
Published: 2023-11-09 (Crawled : 13:00) - globenewswire.com
PDSB | $2.64 -8.97% -9.85% 880K
|
Health Technology
|
| O: 4.94%
H: 4.7%
C: 0.41%
pds0101 biotech cancer trial therapy show
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001140361-23-056240 | 4 | 2023-12-04 | 2023-12-04 | Buy | A | 200000 | 200000 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
MGOL 4 | $0.229 -4.18% 13.72% 420K
|
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
BQ | $0.269 1.51% 11.15% 1.1M
|
Consumer Non-Durables
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
GRFX | $0.2116 -1.58% 7.28% 40K
|
n/a
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10